Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with at least one weight-related...
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.78) by 2...
Met standard bioequivalence (BE) criteria Cmax, AUC0-t, and AUC0-∞Ctrough criterion was metLPCN 1154 was well tolerated with no...
Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company, today announced that Phase 2 results on LPCN 1148 in cirrhosis were ...
Lipocine (NASDAQ:LPCN) reported quarterly earnings of $0.66 per share. This is a 186.84 percent increase over losses of $(0.76)...
Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has bee...
